These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Recognition and management of myocardial ischemia. Prida X; Pepine CJ Compr Ther; 1987 Apr; 13(4):6-11. PubMed ID: 2882886 [No Abstract] [Full Text] [Related]
14. Cardioplegia and myocardial ischemia during cardiopulmonary bypass. Leijala MA Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():175-82. PubMed ID: 3521195 [TBL] [Abstract][Full Text] [Related]
15. [Antianginal and antiadrenergic therapy in acute coronary syndrome]. Raos V; Bergovec M Acta Med Croatica; 2004; 58(2):123-7. PubMed ID: 15208797 [TBL] [Abstract][Full Text] [Related]
16. Calcium channel blockers and ischaemic heart disease: theoretical expectations and clinical experience. Ferrari R; Visioli O Eur Heart J; 1991 Dec; 12 Suppl F():18-24. PubMed ID: 1804637 [TBL] [Abstract][Full Text] [Related]
17. Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. Nayler WG; Panagiotopoulos S; Elz JS; Sturrock WJ Am J Cardiol; 1987 Jan; 59(3):75B-83B. PubMed ID: 2433934 [TBL] [Abstract][Full Text] [Related]
18. Which calcium channel blocker for ischaemic heart disease? Tan K; Lewis S Br J Clin Pract; 1992; 46(1):58-62. PubMed ID: 1419556 [TBL] [Abstract][Full Text] [Related]
19. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats. Sandmann S; Min JY; Meissner A; Unger T Cardiovasc Res; 1999 Oct; 44(1):67-80. PubMed ID: 10615391 [TBL] [Abstract][Full Text] [Related]
20. Perspective: the cellular influences of calcium antagonists on systemic and coronary hemodynamics. Kern MJ Am J Cardiol; 1992 Mar; 69(7):3B-7B. PubMed ID: 1543139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]